Natasha B Leighl, MD, BSc, MMSc

home / authors / natasha-b-leighl-md-bsc-mmsc

Articles

Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial

Subcutaneous Amivantamab vs Intravenous Amivantamab, Both in Combination With Lazertinib, in Refractory EGFR-Mutated, Advanced Non-Small Cell Lung Cancer (NSCLC): Primary Results, Including Overall Survival (OS), From the Global, Phase 3, Randomized Controlled PALOMA-3 Trial

Natasha B Leighl, MD, BSc, MMSc
June 25th 2024

Dr. Natasha Leighl presents the primary results of the phase 3, randomized controlled PALOMA-3 (NCT05388669) trial assessing the overall survival and non-inferiority of subcutaneous amivantamab compared to intravenous amivantamab, in combination with lazertinib, in patients with refractory EGFR-mutated, advanced non-small cell lung cancer.

Read More

Latest Updated Articles

Jens Hoeppner, FAChirg, FACS, MD
Published: June 2nd 2024 | Updated: June 3rd 2024
Perioperative Chemotherapy Prolongs OS vs Neoadjuvant Chemoradiation in Esophageal Cancer
Improving CAR T-Cell Therapy in Multiple Myeloma
Published: July 2nd 2024 | Updated: July 3rd 2024
Improving CAR T-Cell Therapy in Multiple Myeloma
Bradley McGregor, MD
Published: June 4th 2024 | Updated: July 3rd 2024
Dr McGregor on the Rationale for the DAD Trial in Metastatic Urothelial Cancer
Lori Wirth, MD
Published: June 28th 2024 | Updated: July 3rd 2024
Dr Wirth on the Full FDA Approval of Selpercatinib for Advanced RET Fusion+ Thyroid Cancer
Bradley McGregor, MD
Published: June 4th 2024 | Updated: July 3rd 2024
Dr McGregor on the DAD-IO Trial in Treatment-Naive Metastatic Urothelial Carcinoma
Markus Moehler, MD, PhD
Published: July 1st 2024 | Updated: July 3rd 2024
TAP Score and CPS May Be Viable for PD-L1 Expression Measurement in Advanced Gastric Cancers